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Abstract 
Background: Malaria is a widespread infectious disease that threatens a large proportion of the population in tropi-
cal and subtropical areas. Given the emerging resistance against the current standard anti-malaria chemotherapeu-
tics, the development of alternative drugs is urgently needed. New anti-malarials representing chemotypes unrelated 
to currently used drugs have an increased potential for displaying novel mechanisms of action and thus exhibit low 
risk of cross-resistance against established drugs.
Results: Phenotypic screening of a small library (32 kinase-inhibitor analogs) against Plasmodium falciparum NF54-luc 
asexual erythrocytic stage parasites identified a diarylthioether structurally unrelated to registered drugs. Hit expan-
sion led to a series in which the most potent congener displayed nanomolar antiparasitic activity  (IC50 = 39 nM, 3D7 
strain). Structure–activity relationship analysis revealed a thieno[2,3-d]pyrimidine on one side of the thioether linkage 
as a prerequisite for antiplasmodial activity. Within the series, the oxazole derivative KuWei173 showed high potency 
 (IC50 = 75 nM; 3D7 strain), good solubility in aqueous solvents (1.33 mM), and >100-fold selectivity toward human cell 
lines. Rescue experiments identified inhibition of the plasmodial coenzyme A synthesis as a possible mode of action 
for this compound class.
Conclusions: The class of antiplasmodial bishetarylthioethers reported here has been shown to interfere with plas-
modial coenzyme A synthesis, a mechanism of action not yet exploited for registered anti-malarial drugs. The oxazole 
congener KuWei173 displays double-digit nanomolar antiplasmodial activity, selectivity against human cell lines, high 
drug likeness, and thus represents a promising chemical starting point for further drug development.
Keywords: Anti-malaria drugs, Coenzyme A synthesis, Drug discovery, Malaria, 1,3,4-Oxadiazole, Oxazole, Phenotypic 
screening, Plasmodium falciparum, Thieno[2,3-d]pyrimidine, Thioether
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Background
In recent years, the fight against malaria has succeeded 
in a considerable decrease in clinical episodes, based 
on the use of insecticide-treated nets (ITNs), indoor 
residual spraying (IRS), and treatment with combination 
medicines [1]. Nevertheless, each year there are still hun-
dreds of thousands of fatal outcomes from infection with 
Plasmodium [2]. As resistance against older anti-malarial 
drugs, such as chloroquine and pyrimethamine, is wide-
spread [3], the World Health Organization (WHO) rec-
ommends that artemisinin-based combination therapy 
(ACT) should be the first-line treatment for Plasmodium 
falciparum malaria [4]. Despite this approach, arte-
misinin resistance is emerging in South East Asia [5–9]. 
Broad dissemination of artemisinin resistance to other 
malaria endemic regions of the world could lead to a dire 
situation, undoing much of the progress achieved in the 
last decade. As a consequence, the development of anti-
plasmodial drugs based on novel chemotypes and new 
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mechanisms of action is urgently required to ensure effi-
cacious treatment of malaria in the future [2].
With a view to identifying novel anti-malarial chemo-
types that display novel mechanisms, a phenotypic 
screening of 32 compounds comprised of kinase inhibitor 
analogues and other structurally diverse molecules was 
performed. Viability assays on blood stages of transgenic 
P. falciparum parasites that constitutively express lucif-
erase (PfNF54-luc), measuring their bioluminescence in a 
luciferase assay system were employed. Follow-up stud-
ies undertaken with a hit compound revealed structure–
activity relationships in the chemical class, suggestive of 
a specific mechanism of action involving coenzyme A 
synthesis, which ultimately led to the generation of a new 
potent and drug-like antiplasmodial molecule.
Methods
Luciferase‑based viability screening for anti‑malarial 
activity
Asexual erythrocytic stages of transgenic NF54-luc P. fal-
ciparum were used for the luciferase-based viability assay. 
These parasites constitutively express high levels of lucif-
erase. The parasites were cultured as described previously 
[10, 11]. Parasite culture with parasitaemia of 0.5–1% 
was dispensed in triplicate into white 96-well flat-bottom 
plates (each well contains 250 µL) (NUNC, Roskilde, Den-
mark) and incubated in the presence of 3  µM test com-
pounds for 48  h (37  °C, 90%  N2, 5%  CO2, and 5%  O2). 
0.01% DMSO was included in the untreated infected RBC 
cultures as negative control, since the compounds stock 
initially was diluted in DMSO and each treatment well also 
contained 0.01% DMSO. Subsequently, 100 µL RPMI1640 
media was removed from each well and a 100  µL vol-
ume of the Bright-Glo® substrate solution added to each 
well. The resultant cleavage product of the reaction, light, 
was measured using a FLUOROSKAN FL luminometer 
(Thermo), to ascertain viable parasites. Untreated cultures 
were used as negative controls and to calculate the inhi-
bition rate (0% inhibition of parasite growth). Blasticidin 
(Sigma-Aldrich, St. Louis, MO, USA), used for selection 
of transfected parasites, was included as a positive control 
on each plate and gave >90% inhibition of parasite growth 
at concentration 2  µg/mL. Results are summarized in 
Table 1. Compounds with >50% inhibition of viability were 
rated as actives. Experiments were performed in triplicate 
and were repeated at least twice.
Selection and synthesis of additional test molecules
From the initial screening, compound 3a (Fig.  1) was 
identified, representing a chemotype unrelated to estab-
lished antiplasmodial compounds. As additional test 
candidates, congeners of 3a were purchased (3b–3m, 
Fig.  1) from Enamine (Enamine Ltd, Kyiv, Ukraine) or 
synthesized (3n–3s, Fig. 1; 6a–6c, Fig. 2; 8a–8k, Figs. 3, 
4). The syntheses mainly consisted of base-catalyzed 
nucleophilic aromatic substitution reactions, employ-
ing thioxo-substitued heterocycles as nucleophiles and 
electron-poor heterocycles as substrates, with chloro-
substituents as leaving groups. The molecular structure 
of compound 3p was corroborated by an X-ray struc-
ture analysis (refer to Additional file  1). Compounds 3r 
and 3s were prepared from their precursors 3n and 3o, 
respectively, by cleaving off the Boc protection group 
using trifluoroacetic acid and precipitating the aminium 
hydrochlorides with hydrochloric acid from a solution in 
propan-2-ol and diethyl ether. The structural identity of 
all new compounds was confirmed by elemental analysis, 
IR, 1H NMR, 13C NMR and EI mass spectra. The purity 
of all synthesized products was  >95%, determined by 
HPLC. Details of synthesis and characterization of all 
new products are described in Additional file  2. Exem-
plary 1H NMR spectra for compounds 3p, 6d, 8d and 8e 
are shown in Additional file 3.   
Prediction of physicochemical parameters
The prediction of physicochemical parameters rele-
vant for drug likeness was performed by computational 
methods [12]. In the Swiss ADME program package, 
the topological polar surface area (TPSA) is calculated 
according to Ertl et al. [13]. Furthermore, the lipophilic-
ity was predicted according to Wildman et  al. [14], the 
solubility was predicted according to Ali et al. [15], and 
violations of the Pfizer filter for oral bioavailability were 
assessed according to Lipinski et  al. [16]. Results are 
indicated in Table 2.
Cytotoxicity assay: human THP‑1 cell line
The cytotoxicity against THP-1 cells was determined fol-
lowing a protocol described previously [17] with serial 
compound dilutions ranging from 200 to 0.1 μM for cal-
culating the  IC50 values. THP-1 cells were passed into 
fresh THP-1 culture medium [18]. Cells were harvested 
by centrifugation (250×g, 10′, 4  °C), washed three times 
with RPMI 1640 medium, and diluted to 8 ×  105  cells/
mL. The cells were aliquoted in triplicate (125  μL/well) 
into 96-well flat-bottom plates containing compounds 
diluted in complete medium (125  μL/well, containing 
0.01% DMSO). THP-1 cells in wells containing medium 
plus 0.01% DMSO served as negative controls. Cells 
were incubated with test compounds at 37  °C and 5% 
 CO2 for 48  h prior to the addition of 10% Alamar Blue 
(25 μL/well). After an additional 4 h the fluorescence was 
read (λex =  544  nm, λem =  590  nm) using a microplate 
reader (Fluoroskan Ascent FL, Thermo Fisher Scien-
tific, Waltham, MA, USA). Results were analysed using 
Prism 4 (GraphPad Software Inc., La Jolla, CA, USA). 
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Experiments were performed in triplicate and were 
repeated at least twice.
Cytotoxicity assay: human HEK‑293 cell line
Cytotoxicity against human embryonic kidney (HEK-
293) cells was assessed as previously described [19]. 
Briefly, cells were maintained in DMEM medium sup-
plemented with 10% fetal bovine serum at 37 °C and 5% 
 CO2, and routinely split to keep log growth.
Cells were detached using Accutase treatment, then 
seeded into black clear-bottom 384-wells fluorescence 
microplates (Greiner), at a cell density of 44,000 cells/mL 
Table 1 Results of biological evaluation
nd not determined
ID % inhibition, 
PfNF54‑Luc at 3 µM
IC50 [µM], 
Pf3D7 + solvent
IC50 [µM], 
Pf3D7 + 0.8 mM 
CoA
IC50‑ratio (CoA/
solvent)
IC50 [µM], THP‑1 IC50 [µM], HEK‑293
3a 80.8 ± 0.5 0.283 ± 0.073 4.61 ± 0.15 16.3 6.13 >10
3b 25.7 ± 2.0 at 30 µM nd nd – nd nd
3c 37.3 ± 3.7 at 30 µM nd nd – nd nd
3d −0.6 ± 5.4 nd nd – nd nd
3e −7.3 ± 6.9 nd nd – nd nd
3f 1.5 ± 4.3 nd nd – nd nd
3g −13.1 ± 9.1 nd nd – nd nd
3h −103.3 ± 4.4 nd nd – nd nd
3i −5.5 ± 3.8 nd nd – nd nd
3j −11.0 ± 6.7 nd nd – nd nd
3k −7.0 ± 1.8 nd nd – nd nd
3l 24.3 ± 3.2 nd nd – nd nd
3m −8.3 ± 4.1 nd nd – nd nd
3n −0.82 ± 3.11 nd nd – nd nd
3o 2.28 ± 3.31 nd nd – nd nd
3p −14.6 ± 12.9 nd nd – nd nd
3q −12.3 ± 2.2 nd nd – nd nd
3r 7.7 ± 1.8 nd nd – nd nd
3s −2.8 ± 16.6 nd nd – nd nd
6a −24.8 ± 13.6 nd nd – nd nd
6b 1.79 ± 2.53 nd nd – nd nd
6c 0.98 ± 1.52 nd nd – nd nd
8a 33.2 ± 6.8 10.5 ± 1.1 16.1 ± 2.2 1.53 nd >40
8b 4.7 ± 2.6 5.37 ± 1.0 39.7 ± 0.7 7.39 nd >40
8c 96.5 ± 1.6 1.26 ± 0.16 2.31 ± 0.17 1.83 >300 >40
8d 99.9 ± 0.0 0.0388 ± 0.0010 2.61 ± 0.42 67.3 27.5 >10
8e 99.5 ± 0.5 0.0747 ± 0.021 2.58 ± 0.42 34.5 33.6 >10
8f 99.7 ± 0.1 0.0958 ± 0.0063 11.2 ± 2.6 117 11 >4
8g 95.0 ± 1.1 0.0734 ± 0.0022 0.531 ± 0.007 7.23 16.5 >10
8h −1.9 ± 5.3 nd nd – nd nd
8i −18.4 ± 10.6 nd nd – nd nd
8j −36.3 ± 10.6 nd nd – nd nd
8k 98.0 ± 0.2 0.149 ± 0.021 1.06 ± 0.03 7.11 28 >20
BS 99.3 ± 0.7 nd nd – nd nd
Amb 180,780 nd 0.0370 ± 0.0017 1.51 ± 0.19 40.8 nd >40
Chloroqu nd 0.0195 ± 0.0034 0.0271 ± 0.0094 1.39 nd >40
Artemis nd 0.00337 ± 0.00065 0.00490 ± 0.0011 1.45 nd nd
Puromyc nd 0.0338 ± 0.012 0.0939 ± 0.0016 2.78 nd 0.36
Pantoth nd 752 ± 82 >10,000 >13.3 nd nd
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in 45 µL/well, using a Benchtop liquid dispenser (Thermo 
Fisher Multidrop). After seeding, the cells were brought 
back to the incubator and allowed to settle and reattach 
overnight.
The cells were then exposed to the experimental and 
reference compounds in full dose–response using three 
concentrations per log dose (14 points, final concentra-
tion range 40 μM–2 nM) and 0.4% final DMSO concen-
tration. Each plate included 5  µM puromycin and 0.4% 
DMSO as in-plate positive and negative controls, respec-
tively. Plates were incubated at the standard condition 
above for 72 h. At the end of the incubation the medium 
in each well was replaced with 1 mM resazurin, and the 
Fig. 1 Structures and syntheses of 1,3,4-oxadiazole-containing dihetarylthioethers 3. Compounds 3a–m were commercially available. Reagents 
and conditions for 3n–q: i triethylamine, DMF or propan-2-ol, 90–120 °C. 3r and 3s were synthesized from 3n and 3o respectively by cleavage of 
the protecting group with trifluoroacetic acid in dichloromethane
Fig. 2 Synthesis of dihetarylthioethers 6a–c. Reagents and condi-
tions: i triethylamine, DMF, 100–120 °C
Fig. 3 Exemplified synthesis of dihetarylthioether 8a. Reagents and 
conditions: i triethylamine, DMF, 120 °C
http://publikationsserver.tu-braunschweig.de/get/64825
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plates were read using a multilabel microplate reader 
(PerkinElmer Envision) at 530 nm excitation and 595 nm 
emission wavelengths after a further 6 h incubation.
Inhibition data was generated using Office Excel 2013 
(Microsoft).  IC50 values were calculated by fitting a four-
parameter nonlinear regression model using Prism v.6.0 
(Graphpad Software Inc., La Jolla, CA, USA).
Hypothesis building for antiplasmodial mode of action
Taking into account the structure–activity relation-
ships obtained from the entire series of compounds, 
the thieno[2,3-d]pyrimidine and its thioether linkage 
to a second, five-membered heteroaromatic system was 
assumed as a pharmacophore. This substructure resem-
bles that contained in Amb180780 (Fig. 5), an anti-malar-
ial compound that was previously reported to interfere 
with plasmodial coenzyme A (CoA) synthesis [19]. A 
further substructure search in the CAS database of com-
pounds for this pharmacophore revealed an additional 
1667 related compounds, however, no other antiplas-
modial analogue with an assumed or confirmed mode of 
action was found.
Fig. 4 Dihetarylthioethers 8b–k that were synthesized in analogous manner as described for 8a in Fig. 3. For details of synthesis and characteriza-
tion, refer to Additional file 2
Table 2 Physicochemical properties of selected test compounds in comparison to Amb180780
The prediction of physicochemical parameters was performed through Swiss ADME. Calculation of TPSA according to Ertl et al. [13]; lipophilicity prediction according 
to Wildman et al. [14], solubility prediction according to Ali et al. [15]; Lipinski violations according to Lipinski [16]
nd not determined
a Determination of thermodynamic solubility in aqueous buffer (pH 7.4) with shake flask method using HPLC
b MINIMAL detectable concentration of 3a by HPLC/UV
c Equilibrium after 24 h
d Equilibrium after 48 h
ID Mr TPSA Calc. log P S0, exp [µM]
a Log  S0, exp Log  Scalc. Lipinski violations
3a 302.33 131.38 3.49 <1.0b <−6.00 −5.30 0
8c 248.33 97.14 2.58 1.78 × 103 d −2.75 −4.06 0
8d 251.35 120.45 3.30 36.4c −4.44 −4.78 0
8e (Kuwei173) 235.29 105.35 2.83 1.33 × 103 c −2.88 −3.82 0
8f 267.35 159.36 2.28 4.4c −5.36 −5.38 0
8g 284.36 108.00 3.72 0.43d −6.37 −5.82 0
8k 285.35 120.89 3.11 77.0c −4.11 −5.33 0
Amb180780 265.38 120.45 3.61 nd nd −5.94 0
http://publikationsserver.tu-braunschweig.de/get/64825
Page 6 of 10Weidner et al. Malar J  (2017) 16:192 
Coenzyme A rescue assays
Plasmodium falciparum parasites (3D7 strain) were 
grown in RPMI 1640 supplemented with 25 mM HEPES, 
5 mg/mL Albumax II, and 0.37 mM hypoxanthine. Para-
sites were subjected to two rounds of sorbitol synchro-
nization before undergoing compound treatment. Ring 
stage parasites were exposed to the experimental com-
pounds alone, or in combination with 0.8 mM coenzyme 
A (CoA) in 384-wells imaging microplates (CellCarrier, 
PerkinElmer), as previously described [19]. Chloro-
quine, artemisinin, puromycin, and also the CoA path-
way inhibitors panthenol and Amb180780 were used as 
reference compounds. Puromycin 5  µM and untreated 
solvent were used as in-plate positive and negative con-
trols, respectively. Samples were dissolved in DMSO to 
a final assay DMSO concentration of 0.4%. CoA, chlo-
roquine and panthenol were dissolved in water. All the 
compounds were tested in full dose–response using 
three concentrations per log dose (14 points, final con-
centration range 40  μM–2  nM for the experimental 
compounds and puromycin; 10  mM–500  nM for pan-
thenol; 10 µM–0.5 nM for artemisinin and chloroquine). 
All sample and control wells contained the same final 
amounts of solvents. Plates were incubated for 72  h at 
90%  N2, 5%  CO2, 5%  O2, then parasites were stained 
with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine 
(DAPI), and imaged using an Opera QEHS micro-plate 
confocal imaging system (PerkinElmer) with 405  nm 
excitation and 450/50 emission filter, using a 20× water 
immersion objective. Images were analysed as previously 
described [20], to obtain normalized % inhibition data, 
which were then used to calculate  IC50 values, through a 
four parameter logistic curve fitting in GraphPad Prism 
v.6. The experiment was carried out in two independent 
biological replicates, each consisting of two technical 
replicates. Dose–response curves are illustrated in the 
Additional file 4.
Determination of aqueous solubility
The aqueous solubility was determined using a miniatur-
ized shake-flask-method. In brief, the compound (0.25–
1.0  mg) was incubated in a Whatman Mini-Uniprep vial 
with aqueous phosphate buffer, pH 7.4, (300 µL) in an incu-
bation shaker  (IKA® KS 3000 ic control, Staufen, Germany) 
at 25 °C, 400 rpm. Presence of undissolved compound was 
checked at 24 and 48 h. After 24, 48, or 72 h of shaking, the 
filter plunger was punched into the vial and the concentra-
tion in the supernatant was determined by HPLC (AUC 
method, isocratic HPLC, at specific λmax as indicated in the 
Additional file 2). For the calibration, at least three different 
dilutions of the compounds from DMSO stock solutions 
diluted with ACN were quantified. Preparation of buffer 
pH 7.4: to a solution of  Na2HPO4∙2  H2O (290 mg),  K2HPO4 
(20  mg) and NaCl (808  mg) in water (ad 100.0  mL), 12% 
aqueous HCl was added dropwise until the pH reached 
7.4. In the case of 3a the concentration in the supernatant 
was below the limit of quantification. Therefore, the lowest 
concentration (1 µM) used for the calibration was indicated 
as upper limit of solubility in Table 2. Further details of the 
solubility testing methods are described in Additional file 2, 
including calibration concentration ranges, composition 
of chromatographic eluents, and wavelength for measure-
ment of absorbance.
Results
Testing of the compound library revealed structure 3a 
as a hit, which, at a concentration of 3  µM, inhibited 
the viability of erythrocytic asexual stage P. falciparum 
NF54-luc parasites by 80%. Prediction of ADME data by 
the SwissADME interface predicted 3a to be only mod-
erately soluble. To generate structure–activity relation-
ships around 3a, analogues 3b–3q were tested in the 
same assay. Two congeners with ionizable side chains 
(3r, 3s) were included in this test run as compounds with 
predicted improved solubility. All analogues 3 showed, if 
Fig. 5 Structures of published antiplasmodial compounds structurally related to series 8: antiplasmodial compound Amb180780, which interferes 
with the CoA metabolism; compound 33 from Edlin et al. [26]; TCMDC 133557 from the Tres Cantos Antimalarial Set (TCAMS) [27, 28]
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any, only negligible viability reduction when tested on 
PfNF54-luc parasites at 3  µM (Table  1). Analogues 3b 
and 3c were tested in 30  µM concentration, but even 
at this high concentration only inhibited the parasites 
to an extent below 50%, the threshold level for further 
evaluation. While analogues 6a–6c were also completely 
devoid of antiplasmodial activity, members of series 8a–
8k displayed a broad spectrum of potency. The conge-
ners 8b, 8h, 8i, 8j were assessed as inactive. Compound 
8a, the analogue most closely related to 3a, exhibited a 
medium inhibition of viability (33%). However, the other 
structures in the series (8c–8g, 8k) performed well, pro-
ducing  >95% inhibition of viability in 3  µM concentra-
tion. Amb180780 (Fig. 5) is a related structure that was 
recently identified as an inhibitor of the plasmodial CoA 
synthesis pathway (Fig.  6) [19]. Considering the struc-
tural similarity to Amb180780, the hit structure 3a, its 
closely related analogue 8a, and the most potent com-
pounds 8c–8g, 8k were evaluated on 3D7 parasites in 
absence and presence of coenzyme A supplementation. 
Although 8b had shown only minor activity against the 
PfNF54-luc strain, the compound was also evaluated in 
the CoA rescue experiments because of its close struc-
tural similarity to the active 8c. The data from the ini-
tial screening on erythrocytes infected with PfNF54-luc 
strain were nicely congruent with the results with 3D7 
parasites (Table  1). Test compounds showing  >80% 
inhibition in the initial screening produced submicro-
molar  IC50 values against the 3D7 parasites, with 8c 
as the only exception  (IC50  =  1.26  µM). With double-
digit nanomolar inhibitory activity, compounds 8d–8g 
stood out as potent molecules of interest. Supplemen-
tation with 0.8  mM CoA clearly rescued the parasites 
from the inhibitory effects of most of the experimental 
compounds. A clear reduction in the potency of most 
compounds was observed in the CoA-supplemented 
cultures, compared to the solvent controls. With the 
exception of 8a and 8c, all the experimental compounds 
showed  IC50 ratios  (IC50 CoA/IC50 solvent) exceeding a 
threshold of 5×, considered to be significant [21]. The 
most potent compound was 8d, with an  IC50 value of 
0.039  ±  0.001  µM in the absence of CoA. Under CoA 
rescue conditions its  IC50 shifted to 2.6 ±  0.4  µM (67-
fold). KuWei173 (8e) was the third most potent com-
pound against P. falciparum 3D7, showing  IC50 values of 
0.075 ±  0.002 and 2.6 ±  0.4  µM (34-fold) without and 
with CoA supplementation, respectively. The largest  IC50 
shift was observed for 8f, which displayed non-rescue 
and rescue  IC50 values of 0.096  ±  0.006 and  >11  µM, 
respectively (117-fold). 8a and 8c showed only minor 
shifts in their  IC50 values in rescue conditions of ~1.5 and 
1.8 respectively. These compounds were not very potent, 
having non-rescue  IC50s of 10.5 and 1.3 µM, respectively. 
All the control compounds showed the expected behav-
iour in rescue and non-rescue conditions. Chloroquine, 
artemisinin and puromycin displayed the expected  IC50 
values and were not rescued by coenzyme A supplemen-
tation. On the other hand, panthenol and Amb180780 
were both rescued by coenzyme A with  IC50 shifts of 41- 
and >13-fold, respectively.
Tests of the six most potent antiplasmodial compounds 
against human cell lines revealed a low degree of cyto-
toxicity. For example, KuWei173 (8e) which displayed an 
 IC50 = 75 nM against the 3D7 parasites, showed an  IC50 
Pantothenate
4‘-Phosphopantothenate
4‘-Phosphopantothenoylcysteine
4‘-Phosphopantetheine
Dephospho-CoA
Coenzyme A
Pantothenate kinase
Phosphopantothenoyl-
cysteine synthetase
Phosphopantothenoyl-
cysteine decarboxylase
Pantetheinephosphate
adenylyl-transferase
Dephospho-CoA kinase
Fig. 6 Pathway of CoA biosynthesis. Although the enzymatic steps 
are conserved, the homology of the plasmodial and human enzymes 
involved in the pathway is not very high [19, 24]
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of 33.6 µM towards the THP-1 cell line and above 10 µM 
against HEK-293 cells, corresponding to 450- and >133-
fold selectivity, respectively (Table 1).
The aqueous thermodynamic solubility of the com-
pounds showing the highest potency was assessed by a 
shake flask method at pH 7.4 with HPLC quantification. 
The hit structure from the initial screening 3a and the 
benzimidazole 8g exhibited poor solubility below 1 µM. 
While 8d, 8f and 8k were assessed as moderately soluble 
(solubility between 1 and 100 µM), derivatives 8c and 8e 
(KuWei173) exhibited a remarkable solubility of >1 mM. 
In the cases of 8c and 8k considerable differences of 
more than one log value were found between predicted 
and experimentally determined solubility (Table 2).
Discussion
Given the current emerging resistances against arte-
misinin-based drugs, discovery and development of anti-
malarials acting by hitherto unexploited mechanisms is 
urgently needed. Starting points for development cam-
paigns in the field of anti-infectives typically are sourced 
from phenotypic screening. To initiate such a project, 
a small library of 32 structurally diverse compounds 
against asexual erythrocytic stages of PfNF54-Luc para-
sites was screened. Compound 3a was identified as a hit 
that showed no resemblance to established anti-malarial 
compounds and thus offered the possibility of acting via 
a novel mechanism. However, 3a displayed poor solu-
bility, an unfavourable property for a drug development 
(Table  2). For a rational modification of the hit struc-
ture, information on structure–activity relationships 
was needed. The neutral analogues 3b–3q in the initial 
screening system were therefore tested. The ionizable 
amines 3r and 3s were also included in the assays with 
the intention to identify analogues with improved solu-
bility (Fig.  1). Compounds 3b–3s all failed to show the 
desired level of antiplasmodial activity, thus it was specu-
lated that the 2-furyl-1,3,4-oxadiazole system of 3a would 
be an important part of the antiplasmodial pharmacoph-
ore. This hypothesis was refuted by design, synthesis and 
testing of the analogues 6a–c, in which the 2-furyl-1,3,4-
oxadiazole moiety of 3a was retained and the thieno[2,3-
d]pyrimidine was replaced by other heterocycles (Fig. 2). 
Series 6 was completely inactive. Compound 8a, an ana-
logue of 3a in which the oxadiazole oxygen is replaced 
by nitrogen, was then prepared (Fig. 3). Although 8a was 
inferior to 3a, it still showed at least some (33%) inhibi-
tion of the parasites at 3 µM. This result led to the conclu-
sion that the thieno[2,3-d]pyrimidine is an indispensable 
part of the pharmacophore. Consequently, the congeners 
8b–8k, in which the thieno[2,3-d]pyrimidine element is 
kept and connected to various five-membered heteroaro-
matic ring systems by a thioether linkage, were prepared 
(Fig.  4). Taking into account the results from tests on 
both P. falciparum strains, some conclusions were drawn 
regarding the contribution of this second heterocyclic 
element. First, most small heteroaromatic rings were 
tolerated. However, a methyl substituent adjacent to the 
thioether linkage led to decreased antiplasmodial activity 
(analogues 8b and 8c). Benzoannulation at the site oppo-
site to the thioether linkage was tolerated and resulted in 
the very potent derivative 8g. Since 8g shows only sub-
micromolar aqueous solubility, the aza analogue 8k was 
designed, which showed a slightly decreased antiplasmo-
dial activity but remarkably improved solubility by more 
than two orders of magnitude (77 µM). The introduction 
of substituents at the five-position of the benzimidazole 
element completely shut down the antiplasmodial activ-
ity, as was exemplified by 8h, 8i, and 8j. It appears that in 
the binding pocket of an as yet unidentified target protein 
the available space around this position is restricted.
The benchmark for compounds suitable for drug dis-
covery and clinical candidates is an aqueous solubility 
of >60 µg/mL [22], which translates to a 200 µM solution 
for molecules with a molecular mass of ~300 g mol−1. Of 
the compounds showing antiplasmodial activity in this 
study, compounds 8c and 8e (KuWei173) met this demand, 
exhibiting  >1  mM solubility. Since KuWei173 (8e) shows 
17-fold higher antiplasmodial activity it clearly represents 
the most promising result from the present study.
It has been shown that besides aqueous solubility, the 
topological polar surface area (TPSA) is a well-suited 
parameter for the oral bioavailability prediction of drugs. 
As a rule of thumb, molecules displaying less than 60 Å2 
TPSA are absorbed to an extent of  >90%, while com-
pounds with more than 140  Å2 TPSA are absorbed 
by ≤10%. KuWei173 (8e) has a calculated TPSA of 105 Å2 
and, therefore, appears more promising both in terms of 
solubility and permeability than the closely related thia-
zole analogues 3d and Amb180780, which both show 
TPSA values ~120 Å2 (Table 2).
For a rational structure-based drug development pro-
cess with KuWei173 (8e) as the lead compound, the iden-
tification of a biological target in the parasite would be 
of great value. We previously reported that Amb180780 
(Fig.  5), a compound structurally related to 8e, inhibits 
Pf3D7 parasites by interfering with the CoA synthesis 
pathway [19].
Plasmodium falciparum is capable of CoA de-novo 
synthesis and is thus independent of CoA synthesis by 
the host [23]. Although the CoA synthesis pathway is 
highly conserved among eukaryotes (Fig. 6), the homol-
ogy of the five enzymes catalyzing the transformation of 
pantothenate to CoA between Plasmodium and mamma-
lian species is not high [19, 24]. Consequently, the CoA 
synthesis pathway was suggested as a potential target 
http://publikationsserver.tu-braunschweig.de/get/64825
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for antiplasmodial drugs [19, 25]. Considering the struc-
tural similarity to Amb180780, a similar mode of action 
for members of the series 8 was postulated. Upon evalu-
ation of 8a–8g, 8k and 3a for antiplasmodial activity in 
the absence and presence of coenzyme A, we noted that 
CoA supplementation rescued the parasites from inhi-
bition by the compounds, with the exception of 8a and 
8c. The results corroborated the hypothesis that inhibi-
tion of CoA synthesis was a mechanism associated with 
the observed antiplasmodial activity for this series. The 
two outliers 8a and 8c are less active compared to other 
molecules, and may act by other mechanisms than CoA 
synthesis inhibition. Low potency alone, however, does 
not explain lack of rescue by CoA, because 8b, the sec-
ond least potent compound  (IC50  =  6.4  ±  4.3  µM in 
non-rescue conditions) was significantly rescued by CoA 
supplementation to an  IC50 of ~40 µM, corresponding to 
a ~sevenfold shift in activity.
In terms of solubility and antiplasmodial activity 
in  vitro, KuWei173 (8e) appears as the most interesting 
compound resulting from the project reported here. Fol-
low-up studies are now warranted with KuWei173 (8e) 
to assess parameters including metabolic stability and 
in vivo efficacy.
While searching for analogues of series 8 the two anti-
plasmodial thieno[2,3-d]pyrimidines compound 33 [26] 
and TCMDC-124514 [27] (Fig.  5) were also encoun-
tered. The latter was designated as a “quality chemical 
starting point” [27] among the 13,533 hit compounds of 
the Tres Cantos Anti-malarial Set, which resulted from 
the screening of nearly 2 million compounds from GSK 
[28]. Indeed, TCMDC-124514 differs only by one methyl 
group from the compound 8g presented here. To the best 
of our knowledge, neither a systematic structure optimi-
zation study nor a mechanism of antiplasmodial action 
has been published for TCMDC-124514. It is tempt-
ing to speculate that on the one hand TCMDC-124514 
may also act by inhibition of CoA synthesis, and that on 
the other hand the methyl substituent at the ring nitro-
gen may negatively influence the antiplasmodial activ-
ity, considering the results with 8b and 8c. In contrast, 
compound 33, published by Edlin et al. [26], was the best 
compound in a series that was systematically developed 
from a HTS hit. In a Plasmodium berghei infected mouse 
model, compound 33 injected at 50  mg/kg subcutane-
ously over 4 days produced a 34% drop in parasitaemia, 
but failed to prolong the life-span of infected animals. 
The authors rated compound 33 as promising for further 
follow-up through optimization of ADME properties. In 
this respect KuWei173 (8e) can be considered as opti-
mized analogue of compound 33 at least in terms of solu-
bility and potency, although it has not yet been studied 
for metabolic stability in vitro or in vivo malaria models.
For further structure-guided optimization of this com-
pound class, it will be necessary to identify which of 
the enzymes involved in CoA synthesis constitutes the 
eventual target. A recent study using the same rescue 
approach used here, but with additional CoA pathway 
intermediates found that addition of pantethine, dephos-
pho CoA and CoA all rescued the activity of Amb180780 
to more than 75%, pointing at the enzymes phospho-
pantothenoylcysteine synthetase or phosphopantoth-
enoylcysteine decarboxylase as the putative targets for 
Amb180780 [29]. For similar studies aiming at corrobo-
rating the putative targets of the new compound class 
presented here, the readily soluble and potent inhibitor 
KuWei173 (8e) is now available.
Conclusion
A phenotypic screening campaign towards new anti-
plasmodial drugs was performed by testing a compound 
library on PfNF54-luc parasites. Modification of hit struc-
ture 3a led to the simple dihetarylthioether KuWei173 
(8e) which shows high viability inhibition on asexual 
erythrocytic P. falciparum parasites and good water 
solubility. Studies with CoA supplementation showed 
that KuWei173 most probably acts by inhibition of the 
plasmodial CoA synthesis pathway. Cytotoxicity testing 
further revealed a considerable safety margin towards 
human cell lines. Taken together, KuWei173 (8e) appears 
to be a good lead structure for further development and a 
useful tool to study plasmodial CoA biosynthesis.
Abbreviations
ACT: artemisinin-based combination therapy; ADME: absorption, distribution, 
metabolism, excretion; AUC: area under the curve; CAS: chemical abstracts 
service; CoA: coenzyme A; DAPI: 2-(4-amidinophenyl)-1H-indole-6-carbox-
amidine; DMEM: Dulbecco’s modified Eagle’s medium; DMSO: dimethyl 
sulfoxide; EI: electron impact; GSK: GlaxoSmithKline; HEK: human embryonic 
kidney; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HPLC: high 
performance liquid chromatography; HTS: high throughput screening; IC50: 
concentration for 50% inhibition; IR: infra-red; IRS: indoor residual spraying; ITN: 
insecticide-treated net; NMR: nuclear magnetic resonance; RBC: red blood cell; 
RPMI: Roswell Park Memorial Institute; THP-1: a human monocytic leukemia 
cell line; TPSA: topological polar surface area; WHO: World Health Organization.
Authors’ contributions
TW, LL, AN, LP, PGJ performed experiments and analysed the data. CK, RD, VMA 
designed the studies. All authors drafted or revised the paper. All authors read 
and approved the final manuscript.
Additional files
Additional file 1. X-ray structure analysis of test compound 3p.
Additional file 2. Synthesis procedures and characterization of test com-
pounds 3n–3s, 6a–6c, 8a–8k and details of solubility testing.
Additional file 3. 1H NMR spectra of test compounds 3p, 6d, 8d, 8e.
Additional file 4. Dose–response plots for test compounds and refer-
ence drugs showing parasite viability (3D7) in absence and presence of 
coenzyme A.
http://publikationsserver.tu-braunschweig.de/get/64825
Page 10 of 10Weidner et al. Malar J  (2017) 16:192 
Author details
1 Institut für Medizinische und Pharmazeutische Chemie, Technische Uni-
versität Braunschweig, Beethovenstraße 55, 38106 Braunschweig, Germany. 
2 Discovery Biology, Griffith Institute for Drug Discovery, Griffith University, 
Nathan 4111, QLD, Australia. 3 Department of Microbiology and Molecular 
Genetics, IMRIC, The Kuvin Center for the Study of Infectious and Tropical 
Diseases, The Hebrew University-Hadassah Medical School, 91120 Jerusalem, 
Israel. 4 Institut für Anorganische und Analytische Chemie, Technische Univer-
sität Braunschweig, Hagenring 30, 38106 Braunschweig, Germany. 5 Center 
of Pharmaceutical Engineering (PVZ), Technische Universität Braunschweig, 
Franz-Liszt-Straße 35A, 38106 Braunschweig, Germany. 
Acknowledgements
The project was funded by the German Federal Ministry of Education and 
Research (BMBF BioDisc 7; 13GW0024) awarded to RD and CK and an Austral-
ian Research Council LP120200557 awarded to VMA. Support by the COST 
action CM1307 “Targeted chemotherapy towards diseases caused by endo-
parasites” (to TW and CK) is gratefully acknowledged. We thank the Australian 
Red Cross Blood Bank for the provision of human red blood cells.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The data generated or analysed during this study are included in this pub-
lished article and its Additional files 1, 2, 3 and 4.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 6 February 2017   Accepted: 26 April 2017
References
 1. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Design-
ing the next generation of medicines for malaria control and eradication. 
Malar J. 2013;12:187.
 2. Wells TN, van Huijsduijnen RH, Van Voorhis WC. Malaria medicines: a glass 
half full? Nat Rev Drug Discov. 2015;14:424–42.
 3. Fidock DA. Drug discovery: priming the antimalarial pipeline. Nature. 
2010;465:297–8.
 4. Bosman A, Mendis KN. A major transition in malaria treatment: the adop-
tion and deployment of artemisinin-based combination therapies. Am J 
Trop Med Hyg. 2007;77:193–7.
 5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Arte-
misinin resistance in Plasmodium falciparum malaria. N Engl J Med. 
2009;361:455–67.
 6. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga 
C, et al. Genetic architecture of artemisinin-resistant Plasmodium falcipa-
rum. Nat Genet. 2015;47:226–34.
 7. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. 
Emergence of artemisinin-resistant malaria on the western border of 
Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
 8. Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, 
et al. Drug resistance. K13-propeller mutations confer artemisinin resist-
ance in Plasmodium falciparum clinical isolates. Science. 2015;347:428–31.
 9. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Step-
niewska K, et al. Hyperparasitaemia and low dosing are an important 
source of anti-malarial drug resistance. Malar J. 2009;8:253.
 10. Dzikowski R, Frank M, Deitsch K. Mutually exclusive expression of viru-
lence genes by malaria parasites is regulated independently of antigen 
production. PLoS Pathog. 2006;2:e22.
 11. Fugel W, Oberholzer AE, Gschloessl B, Dzikowski R, Pressburger N, Preu 
L, et al. 3,6-Diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-b]pyridine-
5-carbonitriles are selective inhibitors of Plasmodium falciparum glycogen 
synthase kinase-3. J Med Chem. 2013;56:264–75.
 12. Molecular modelling group of the swiss institute of bioinformatics: swiss 
ADME. 2016. http://www.swissadme.ch. Accessed 12 Oct 2016.
 13. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as 
a sum of fragment-based contributions and its application to the predic-
tion of drug transport properties. J Med Chem. 2000;43:3714–7.
 14. Wildman SA, Crippen GM. Prediction of physicochemical parameters by 
atomic contributions. J Chem Inf Comput Sci. 1999;39:868–73.
 15. Ali J, Camilleri P, Brown MB, Hutt AJ, Kirton SB. Revisiting the general 
solubility equation: in silico prediction of aqueous solubility incorporat-
ing the effect of topographical polar surface area. J Chem Inf Model. 
2012;52:420–8.
 16. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and com-
putational approaches to estimate solubility and permeability in drug 
discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
 17. Ryczak J, Papini M, Lader A, Nasereddin A, Kopelyanskiy D, Preu L, et al. 
2-Arylpaullones are selective antitrypanosomal agents. Eur J Med Chem. 
2013;64:396–400.
 18. Reichwald C, Shimony O, Dunkel U, Sacerdoti-Sierra N, Jaffe CL, Kunick C. 
2-(3-aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial 
chemotype. J Med Chem. 2008;51:659–65.
 19. Fletcher S, Avery VM. A novel approach for the discovery of chemically 
diverse anti-malarial compounds targeting the Plasmodium falciparum 
coenzyme A synthesis pathway. Malar J. 2014;13:343.
 20. Duffy S, Avery VM. Development and optimization of a novel 384-well 
anti-malarial imaging assay validated for high-throughput screening. Am 
J Trop Med Hyg. 2012;86:84–92.
 21. Chugh M, Scheurer C, Sax S, Bilsland E, van Schalkwyk DA, Wicht KJ, et al. 
Identification and deconvolution of cross-resistance signals from anti-
malarial compounds using multidrug-resistant Plasmodium falciparum 
strains. Antimicrob Agents Chemother. 2015;59:1110–8.
 22. Kerns EH, Di L, Carter GT. In vitro solubility assays in drug discovery. Curr 
Drug Metab. 2008;9:879–85.
 23. Spry C, Saliba KJ. The human malaria parasite Plasmodium falciparum 
is not dependent on host coenzyme A biosynthesis. J Biol Chem. 
2009;284:24904–13.
 24. Huthmacher C, Hoppe A, Bulik S, Holzhutter HG. Antimalarial drug targets 
in Plasmodium falciparum predicted by stage-specific metabolic network 
analysis. BMC Syst Biol. 2010;4:120.
 25. Spry C, Chai CL, Kirk K, Saliba KJ. A class of pantothenic acid analogs 
inhibits Plasmodium falciparum pantothenate kinase and represses 
the proliferation of malaria parasites. Antimicrob Agents Chemother. 
2005;49:4649–57.
 26. Edlin CD, Morgans G, Winks S, Duffy S, Avery VM, Wittlin S, et al. 
Identification and in vitro ADME assessment of a series of novel anti-
malarial agents suitable for hit-to-lead chemistry. ACS Med Chem Lett. 
2012;3:570–3.
 27. Calderon F, Barros D, Bueno JM, Coteron JM, Fernandez E, Gamo FJ, et al. 
An invitation to open innovation in malaria drug discovery: 47 quality 
starting points from the TCAMS. ACS Med Chem Lett. 2011;2:741–6.
 28. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, et al. 
Thousands of chemical starting points for antimalarial lead identification. 
Nature. 2010;465:305–10.
 29. Fletcher S, Lucantoni L, Sykes ML, Jones AJ, Holleran JP, Saliba KJ, et al. 
Biological characterization of chemically diverse compounds targeting 
the Plasmodium falciparum coenzyme A synthesis pathway. Parasit Vec-
tors. 2016;9:589.
http://publikationsserver.tu-braunschweig.de/get/64825
